Lucid Biosystems (Lucid) is a US-based biotechnology company that uses proprietary technology to create personalized cell therapies to treat solid tumors. Lucid’s platform functionally identifies and recovers rare, natively-active T-cells directly from a patient’s tumor. Using single-cell functional assays, high-throughput microcapillary technology, and RNA sequencing, Lucid derives patient-specific T-cell receptor (TCR) sequences that are proven before therapeutic use. The platform is tumor-agnostic and directly addresses tumor heterogeneity - the central challenge in solid-tumor immunotherapy - by leveraging the natural diversity of the human adaptive immune system and selecting only the most relevant clonotypes. Furthermore, to improve accessibility across the spectrum of health providers, Lucid has an objective to reduce cost per patient to approximately $50,000 per dose. Lucid is currently raising capital to advance to pre-IND readiness.